Member access

4-Traders Homepage  >  Shares  >  SIX SWISS EXCHANGE AG  >  Roche Holding Ltd.       CH0012032048

 SummaryNewsCalendarCompanyFinancialsConsensusRevisions 
Company
Roche Holding AG is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics.As a large biotech company, Roche has truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and neuroscience.It is also a leader in in-vitro... 
Sector
Pharmaceuticals
Calendar
10/16 | 08:00amSales and Revenue Call
Surperformance© rating of Roche Holding Ltd.
Trading Rating : Investor Rating :
More about the company
Financials ( CHF)
Sales 2014 47 260 M
EBIT 2014 17 454 M
Net income 2014 12 114 M
Debt 2014 5 095 M
Yield 2014 2,90%
Sales 2015 49 204 M
EBIT 2015 18 548 M
Net income 2015 13 065 M
Finance 2015 697 M
Yield 2015 3,11%
PER 2014 20,03
PER 2015 18,37
EV / Sales 2014 5,25x
EV / Sales 2015 4,93x
Capitalization 243 216 M
More Financials
Latest news on ROCHE HOLDING LTD.
2d ago ROCHE : Genentech :’s Investigational Combination of Cobimetinib Plus Zelb..
3d ago ROCHE : Genentech :’s Perjeta Regimen Extended the Lives of People With an..
7d ago Adaptimmune raises $104 million to develop immune-system cancer drugs
09/17 For Roche CEO, celebrating failure is key to success
09/16 Roche's $8 billion InterMune buy not a signal for more big deals
09/08 Cost a focus as GSK takes lead in new wave of biotech lung drugs
09/04 Roche rules out mega deals, open to smaller ones - paper
09/04 Ex-Genentech boss Levinson resigns from Roche's board
09/03 Google's Calico, AbbVie forge deal against diseases of aging
08/27 InterMune drug may offer big upside to Roche if aimed at liver
08/25DJMARKET SNAPSHOT : S&P 500 Jumps To Record Close Just Below 2,000
08/25 S&P 500 sets record high but fails to hold 2,000 mark
More news
Comments 
Advertisement
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions
Dynamic quotes  
ON
| OFF